Latest news with #AMR
Yahoo
3 days ago
- Business
- Yahoo
Itron Celebrates Shipment of 2 Millionth Cyble™ 5 Communication Module
French Water Provider, Metz Eurométropole Water Utility, Receives Milestone Module LIBERTY LAKE, Wash., June 25, 2025 (GLOBE NEWSWIRE) -- Itron, Inc. (NASDAQ: ITRI), which is innovating new ways for utilities and cities to manage energy and water, has shipped more than 2 million of its Cyble 5 multi-connectivity communication modules. French water utility, Metz Eurométropole, is the recipient of the two millionth module. The water provider is deploying Itron Cyble 5-equipped water meters in support of its migration from automated meter reading (AMR) to advanced metering infrastructure (AMI) and ongoing efforts to streamline operations and improve the customer experience. Itron's Cyble 5 communication module transforms raw data into actionable intelligence, enabling real-time monitoring, advanced analytics and consumption insights. This empowers water providers, like the Metz Eurométropole Water Utility, to make data-driven decisions, leading to optimized operations and improved service delivery. With its durable design and advanced open standards compatibility, the Cyble 5 is a strategic investment, helping Metz Eurométropole Water Utility turn its ambitious water management goals into a near-term reality. Metz Eurométropole Water Utility, which provides water services to more than 47,000 people across eastern France, takes advantage of the module's key differentiators, including: Durable Design: Built to withstand harsh environments with IP68-rated protection against water, dust and extreme conditions to help lower maintenance and meter replacement costs Interoperability with Open-Standards: Seamlessly integrates with AMR, AMI and IoT networks, ensuring compatibility across utility systems. Billing Index & Consumption Data Logging: Provides accurate, time-stamped consumption data for accurate billing, leak detection and analytics to protect revenue and improve customer satisfaction Mobile Meter Reading: Enables fast, reliable data collection via walk-by or drive-by methods, lowering operating and labor costs. The module is connected to Metz Eurométropole Water Utility's LoRaWAN AMI network, enabling two-way communication between meter endpoints and the utility and delivery of timely, extensive data sets. With its embedded multi-connectivity options, the Cyble 5 communication module adapts to complex deployments and evolves with the needs from the field. Since deployment began in 2022, the water provider has gained the ability to proactively prevent and reduce leaks, optimize resource allocation and ensure billing accuracy. 'Metz Eurométropole Water Utility is thrilled to be the recipient of Itron's two millionth Cyble 5 communication module. The solution has proved instrumental in transforming our water management, making it more sustainable, customer centric and intelligent,' said Morgane Pitel, Director of Metz Eurométropole Water Utility. 'The Cyble 5 module gives us and our users near real-time access to water consumption data. With this level of insight, we can better understand usage patterns, detect leaks earlier and ultimately support users in managing their water consumption. It helps us move toward greater efficiency in order to preserve this vital resource. The improved data management helps us target investment more effectively — allowing us to reinvest savings into expanding smart water solutions across our network.' 'This milestone marks a pivotal moment for Itron and our customers. The shipment of two million Cyble 5 communication modules reflects our ongoing commitment to protecting our precious water supply and providing global water providers, like Metz Eurométropole Water Utility, with modern solutions that connect every drop,' said Justin Partrick, senior vice president of Devices at Itron. 'As water demand rises alongside changing consumer expectations, climate disruption and urbanization, there has never been a more critical time to invest in smarter, more agile operations. We are excited to continue partnering with water providers worldwide, transforming their distribution systems into connected, intelligent networks that deliver real-time insights and operational excellence.' Cyble 5 communication modules easily transform mechanical meters into communicating devices to keep operations running smoothly — while ensuring accurate billing and maximizing revenue. To learn more, see the product brochure. About Itron Itron is a proven global leader in energy, water, smart city, IIoT and intelligent infrastructure services. For utilities, cities and society, we build innovative systems, create new efficiencies, connect communities, encourage conservation and increase resourcefulness. By safeguarding our invaluable natural resources today and tomorrow, we improve the quality of life for people around the world. Join us: Itron®, the Itron Logo and Cyble are registered trademarks of Itron, Inc in the United States and/or other countries and regions. All third-party trademarks are property of their respective owners and any usage herein does not suggest or imply any relationship between Itron and the third party unless expressly stated. For additional information, contact: Itron, Inc. Alison MallahanSenior Manager, Corporate Communications509-891-3802PR@ Paul VincentVice President, Investor Relations512-560-1172Investors@ Itron, Inc. LinkedIn: X: Newsroom: Blog:
Globe and Mail
4 days ago
- Health
- Globe and Mail
Kidney Transplant Rejection Therapeutics Market Size in 7MM is expected to grow at a decent CAGR by 2034, estimates DelveInsight
DelveInsight's 'Kidney Transplant Rejection Market Insights, Epidemiology, and Market Forecast – 2034' report delivers an in-depth understanding of kidney transplant rejection, historical and forecasted epidemiology, as well as the kidney transplant rejection therapeutics market trends in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. Unlock key insights into the Kidney Transplant Rejection Market! Download DelveInsight's comprehensive report to explore market trends, pipeline analysis, and emerging therapies @ Kidney Transplant Rejection Market Size Key Takeaways from the Kidney Transplant Rejection Market Report In June 2025, Biogen announced a clinical trial is to evaluate the efficacy of felzartamab compared to placebo in kidney transplant recipients diagnosed with late active or chronic active AMR. In June 2025, Tract Therapeutics Inc. organized a Phase 2 trial is to determine the safety and efficacy of administering expanded regulatory T cells (TRK-001) to prevent allograft rejection in living donor renal transplant recipients. In 2023, there were an estimated 44 thousand total incident cases of kidney transplants across the 7MM, with the number expected to rise by 2034. According to DelveInsight's estimates, there were approximately 27 thousand incident cases of kidney transplants across the US in 2023, with the number expected to rise by 2034. In 2023, the US reported approximately 2 thousand acute and 8 thousand chronic cases of kidney transplant rejection, with these numbers expected to increase by 2034. In 2023, among EU4 and the UK, the UK reported the highest number of living kidney transplants, with approximately 46 thousand instances, followed by France, with nearly 45 thousand cases. In contrast, Italy recorded the lowest, with around 28 thousand cases. In 2023, EU4 and the UK reported approximately 2 thousand acute and 4 thousand chronic cases of kidney transplant rejection. By 2034, these numbers are expected to increase to nearly 4 thousand acute cases and 7 thousand chronic cases. In 2023, Japan had approximately 2 thousand incident cases of kidney transplants. This number is projected to rise by 2034, growing at a CAGR of 0.7%. The leading Kidney Transplant Rejection Companies such as Amgen Inc, Amyndas Pharmaceuticals LLC, Astellas Pharma Inc, Bristol-Myers Squibb Co, Alphamab Oncology, AltruBio Inc, Cynata Therapeutics Ltd, Eledon Pharmaceuticals Inc, Enceladus Pharmaceuticals BV, Hansa Biopharma AB, Helocyte Bi, and others. Promising Kidney Transplant Rejection Pipeline Therapies such as Sonazoid, Belatacept, VIB4920, Thymoglobulin, AT-1501, Tacrolimus, Simulect, Belimumab and others. Stay ahead in the competitive landscape of the Kidney Transplant Rejection Market. Access DelveInsight's in-depth market analysis and strategic insights today! Click here for more @ Kidney Transplant Rejection Treatment Market Size Kidney Transplant Rejection Epidemiology Segmentation in the 7MM Total Kidney Transplant Rejection Incident Cases Total Kidney Transplant Rejection Living Cases Kidney Transplant Rejection Type-specific Cases Download the report to understand which factors are driving Kidney Transplant Rejection epidemiology trends @ Kidney Transplant Rejection Prevalence Marketed Kidney Transplant Rejection Prophylaxis Drugs MYHIBBIN: Azurity Pharmaceuticals MYHIBBIN, developed by Azurity Pharmaceuticals, is the first ready-to-use mycophenolate mofetil (MMF) oral suspension approved for preventing organ rejection in patients aged 3 months and older who have received allogeneic kidney, heart, or liver transplants. Approved by the US FDA in May 2024, MYHIBBIN is intended for use in combination with other immunosuppressive therapies. The product works by inhibiting inosine monophosphate dehydrogenase (IMPDH), a key enzyme in the de novo guanosine nucleotide synthesis pathway, leading to the suppression of T and B lymphocyte proliferation and cytokine production, which prevents graft rejection. THYMOGLOBULIN: Sanofi THYMOGLOBULIN, developed by Sanofi, is an immunosuppressive therapy derived from rabbit serum through immunization with human thymocytes. This purified, pasteurized IgG product targets T lymphocyte antigens and is designed for the prevention of acute kidney transplant rejection. Administered via intravenous infusion, it exerts therapeutic effects by clearing circulating T cells and modulating their activation, homing, and cytotoxic functions. Its mechanism includes targeting multiple T-cell markers, such as CD2, CD3, CD4, and HLA-DR, promoting immune suppression and reducing the risk of transplant rejection. NULOJIX: Bristol Myers Squibb NULOJIX (belatacept), developed by Bristol Myers Squibb, is a selective T-cell costimulation blocker approved for the prevention of organ rejection in adult kidney transplant recipients. Administered via intravenous infusion, NULOJIX is used alongside basiliximab induction, mycophenolate mofetil, and corticosteroids. Its mechanism of action involves targeting CD80 and CD86 on antigen-presenting cells, thereby preventing CD28-mediated T-cell activation, a key driver of immunologic rejection. This results in reduced T-cell proliferation and cytokine production, including interleukin-2 and TNF-a, mitigating the immune response in transplant rejection. Emerging Kidney Transplant Rejection Drugs MDR-101: Medeor Therapeutics MDR-101, developed by Medeor Therapeutics, is an innovative cellular therapy derived from the blood and peripheral stem cells of a living kidney donor. The therapy is designed to induce donor-specific immune tolerance, effectively preventing kidney transplant rejection. By reprogramming the recipient's immune system to accept the donor organ, MDR-101 eliminates the need for lifelong immunosuppressive drugs and their associated side effects, thereby enhancing transplant kidney function and long-term survival. Positive interim data from a Phase III trial, presented as a late-breaking oral presentation at the American Society of Nephrology (ASN) Kidney Week in November 2023, highlighted its potential as a breakthrough in transplantation medicine. MDR-101 has received ODD in both the US and EU. The clinical trial is being conducted under an FDA Special Protocol Assessment (SPA). In September 2020, the US FDA also granted Regenerative Medicine Advanced Therapy (RMAT) designation to MDR-101 for the prevention of kidney transplant rejection. Further, in January 2018, the California Institute for Regenerative Medicine (CIRM) awarded USD 18.8 million to support the Phase III clinical trial under its clinical trial funding initiative. Tegoprubart (AT-1501): Eledon Pharmaceuticals Tegoprubart, developed by Eledon Pharmaceuticals, is a humanized monoclonal antibody targeting the CD40L pathway, designed to prevent kidney transplant rejection by blocking the CD40-CD40L interaction. This innovative immunosuppressive therapy aims to replace traditional calcineurin inhibitors (CNIs), such as tacrolimus, potentially improving long-term graft survival and patient outcomes. In September 2024, Eledon completed enrollment for the Phase II BESTOW trial, four months ahead of schedule, with topline results anticipated in Q4 2025. Phase Ib trial data presented at the American Transplant Congress (ATC) in June 2024 demonstrated the drug's safety and tolerability. Riliprubart (BIVV020, SAR445088): Sanofi Riliprubart, developed by Sanofi, is an IgG4 humanized monoclonal antibody under investigation for the treatment of Antibody-Mediated Rejection (AMR) in kidney transplants. The drug works by selectively inhibiting activated complement component C1s, a critical mediator of the inflammatory processes associated with AMR. Phase II clinical trials are currently underway to evaluate the efficacy and safety of Riliprubart in patients diagnosed with or at risk of AMR. Administered intravenously, Riliprubart represents a promising therapeutic approach to addressing AMR in kidney transplant recipients. Discover the future of Kidney Transplant Rejection Treatments with DelveInsight's latest market report. Get expert insights and forecasts—download now! @ Kidney Transplant Rejection Market Drivers and Barriers Kidney Transplant Rejection Market Outlook Kidney transplant rejection is a major concern for recipients, as it can severely affect the long-term success and function of the transplanted organ. Rejection happens when the recipient's immune system recognizes the donor kidney as foreign, prompting an immune response that damages the graft. There are two main types of rejection: Acute, which usually occurs within the first-year after transplantation, and chronic, which develops gradually over several years and is more prevalent. Chronic rejection is often associated with insufficient immunosuppression or non-compliance with medication regimens, leading to ongoing immune attacks that result in scarring and eventual loss of kidney function. Around 15–20% of transplant recipients experience some form of rejection, highlighting the importance of regular monitoring and strict adherence to immunosuppressive therapy to reduce this risk. Kidney Transplant Rejection Drugs Market Insights Currently, a variety of medication approaches for kidney transplant rejection prophylaxis involve approved treatments that utilize different mechanisms of action to support long-term transplant success. These include ENVARSUS XR, IDEFIRIX, NULOJIX, THYMOGLOBULIN, MYHIBBIN, and SIMULECT, among others, all of which play a crucial role in managing immune responses and minimizing the risk of rejection. Kidney transplant rejection aims to manage immune responses, prevent further organ damage, and ensure long-term transplant success. Treatment involves a combination of immunosuppressive therapies, close monitoring, and supportive care to address acute and chronic rejection. Key goals include preserving graft function, reducing inflammation, minimizing complications, and improving the patient's quality of life. Lifestyle adjustments, including dietary management and adherence to medication regimens, are essential for long-term success. While challenges remain, ongoing research is focused on advancing therapies to enhance graft survival and improve outcomes for transplant recipients. Explore the dynamics of the Kidney Transplant Rejection Market with DelveInsight. From market size to emerging drugs—find it all in our latest report. Read now! @ Kidney Transplant Rejection Ongoing Clinical Trials Analysis Scope of the Kidney Transplant Rejection Market Report Coverage- 7MM Study Period- 2020-2034 Kidney Transplant Rejection Companies- Amgen Inc, Amyndas Pharmaceuticals LLC, Astellas Pharma Inc, Bristol-Myers Squibb Co, Alphamab Oncology, AltruBio Inc, Cynata Therapeutics Ltd, Eledon Pharmaceuticals Inc, Enceladus Pharmaceuticals BV, Hansa Biopharma AB, Helocyte Bi, and others. Kidney Transplant Rejection Pipeline Therapies- Sonazoid, Belatacept, VIB4920, Thymoglobulin, AT-1501, Tacrolimus, Simulect, Belimumab and others. Kidney Transplant Rejection Therapeutic Assessment: Kidney Transplant Rejection Current Marketed and Kidney Transplant Rejection Emerging Therapies Kidney Transplant Rejection Market Dynamics: Kidney Transplant Rejection market drivers and Kidney Transplant Rejection market barriers Kidney Transplant Rejection Unmet Needs, KOL's views, Analyst's views, Kidney Transplant Rejection Market Access and Reimbursement Table of Contents 1. Key Insights 2. Report Introduction 3. Market Overview at a Glance 4. Executive Summary 5. Key Events 6. Disease Background and Overview 7. Methodology 8. Epidemiology and Patient Population 9. Patient Journey 10. Marketed Drugs 11. Emerging Drugs 12. Kidney Transplant Rejection – 7MM Market Analysis 13. KOL Views 14. Unmet Needs 15. SWOT Analysis 16. Market Access and Reimbursement 17. Appendix 18. DelveInsight Capabilities 19. Disclaimer 20. About DelveInsight About Us DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve. Media Contact Company Name: DelveInsight Business Research LLP Contact Person: Yash Bhardwaj Email: Send Email Phone: 09650213330 Address: 304 S. Jones Blvd #2432 City: Las Vegas State: NV Country: United States Website:
Kuwait Times
4 days ago
- Health
- Kuwait Times
Kuwait, WHO launch research partnership to combat drug resistance
KUWAIT: Kuwait is taking steps to combat antimicrobial resistance (AMR), a growing global health threat, through a strategic research partnership between the Kuwait Institute for Scientific Research (KISR), the Ministry of Health, and the World Health Organization (WHO). A preparatory meeting was held on Tuesday to set the stage for a series of collaborative scientific and technical initiatives aimed at enhancing public health research and policy coordination under the 'One Health' approach, which considers human, animal, and environmental health as interlinked. The meeting brought together key stakeholders from across Kuwait's scientific and health institutions, marking the first step in implementing a memorandum of understanding (MoU) signed earlier this year between KISR and WHO. The MoU, finalized in January 2025, focuses on strengthening national research capacity to tackle complex public health issues, particularly communicable diseases (such as diabetes and obesity), environmental pollution, pandemic preparedness, and AMR. Dr Faisal Al-Humaidan, Acting Director General of KISR, highlighted the urgency of addressing AMR and praised the collaborative framework being established through this partnership. 'The spread of antimicrobial resistance poses a serious risk to the quality of life, the effectiveness of healthcare services, and the financial sustainability of national resources,' he told Kuwait News Agency (KUNA). 'This cooperation will contribute to translating research findings into scientifically based policies that can improve the health situation in the country.' Dr Al-Humaidan also acknowledged the Ministry of Health's strong engagement in the initiative, particularly the contributions of Assistant Undersecretary for Public Health Affairs, Dr Al-Munther Al-Hasawi, and the Antimicrobial Resistance Unit at the Kuwait Center for Disease Prevention and Control. Their involvement, he said, underscores the national commitment to proactively address AMR as a priority health issue. Also speaking at the meeting, Dr Abdullah Al-Enezi, Acting Executive Director of the Environment and Life Sciences Research Center at KISR, described AMR as one of the most pressing health challenges facing Kuwait and the region. 'The ability to confront AMR depends on building a strong scientific knowledge base and using it to develop and implement sound public health strategies,' he said. Dr. Al-Enezi also noted the important role played by national institutions such as the Kuwait Foundation for the Advancement of Sciences, which has provided continued support for research in this field. Representing the WHO, Dr Assad Hafeez emphasized the significance of integrating local and international efforts to tackle AMR through the One Health approach. 'This successful cooperation between national and international institutions is a practical step toward building a comprehensive national system to confront antimicrobial resistance,' he said in a press release. 'WHO is fully committed to supporting Kuwait in turning this vision into reality by translating scientific findings into concrete, effective policies and practices.' The meeting included representatives from several prominent Kuwaiti entities involved in health, research, and environmental management, including Kuwait University's Faculty of Medicine, the Environment Public Authority, the Public Authority for Food and Nutrition, and the Public Authority for Agricultural Affairs and Fish Resources. Participants discussed initial frameworks for cooperation, identified priority research areas, and explored pathways for translating scientific outputs into actionable health policies. The initiative aligns with global efforts to curb the spread of resistant pathogens, which are increasingly undermining the effectiveness of antibiotics and other antimicrobial treatments. According to health experts, failure to act now could result in a future where common infections become harder — and in some cases impossible — to treat, leading to longer illnesses, more hospitalizations, and higher mortality rates. — Agencies
Arab Times
4 days ago
- Health
- Arab Times
Kuwait moves to strengthen public health research infrastructure
KUWAIT CITY, June 24: In a move to strengthen Kuwait's public health research infrastructure, the Kuwait Institute for Scientific Research (KISR) held a preliminary meeting on Tuesday with the Ministry of Health (MOH) and the World Health Organization (WHO). The discussion focused on enhancing collaborative research in key public health areas, particularly antimicrobial resistance (AMR) and its growing impact on humans, animals, and the environment. KISR's Acting Director General, Faisal Al-Humaidan, emphasized the significance of scientific and technical cooperation among the three entities in addressing AMR under the 'One Health' approach — a globally endorsed framework that recognizes the interconnectedness of human, animal, and environmental health. 'This meeting serves to activate the memorandum of understanding signed earlier this year between KISR and WHO,' Al-Humaidan said in a press statement. 'The MoU outlines collaborative efforts to advance research in several critical areas, including non-communicable diseases like diabetes and obesity, environmental pollution, epidemic preparedness, and antimicrobial resistance — all of which directly affect public health outcomes, service delivery, and the sustainability of national financial resources.' Dr. Abdullah Al-Enezi, Acting Executive Director of KISR's Environment and Life Sciences Research Center, described AMR as a national health priority. He called for expanding the country's scientific knowledge base to develop evidence-driven policies to confront this pressing issue. Al-Enezi also acknowledged the support of the Kuwait Foundation for the Advancement of Sciences (KFAS) and other relevant national entities in promoting research-led solutions. Representing the WHO, Dr. Asaad Hafeez commended the collaborative efforts between the international organization, KISR, and Kuwait's health authorities. He underlined the importance of these partnerships in establishing a robust national response to AMR aligned with the 'One Health' strategy. Dr. Hafeez further revealed that the WHO is working toward establishing a research cooperation center at KISR. This proposed center would facilitate the exchange of scientific expertise and help formulate comprehensive national strategies to mitigate the risks associated with antimicrobial resistance. He reaffirmed WHO's full commitment to supporting Kuwait in transforming this integrated approach into actionable policies and impactful health practices.
Fox Sports
6 days ago
- Automotive
- Fox Sports
Cold Beer From Fan Helps Santino Ferrucci Celebrate Hot Streak
INDYCAR Which was better Sunday at Road America? Santino Ferrucci's drive in the XPEL Grand Prix at Road America Presented by AMR or his catch of a fan's cold beer in Turn 1 after climbing from the car on this excruciatingly hot day? Give him high marks for both. The combination of the two continued what has been an outstanding few weeks for AJ Foyt Racing's veteran driver. This third-place finish earned him a fourth-consecutive top-five finish, pushing him to ninth in the championship standings as the second half of the season begins. The exhausted and likely dehydrated Ferrucci got to Road America's finish line and could do no more. Actually, his No. 14 Sexton Properties/AJ Foyt Racing Chevrolet could do no more, as well. It was fuel deprived, and it came to a stop in Turn 1 with its fuel cell empty. The always-spunky Ferrucci climbed from the cockpit, slowly removed his helmet and then seemed inspired by the reception of the fans gathered in that part of the 14-turn, 4.014-mile road course. One tossed him a water bottle, although it sailed over his head and landed there in the sand trap. Ferrucci retrieved it and absorbed as much as he could in one long gulp. Then came a better offer from that same infield section – it was a cold can of Miller Lite. Ferrucci didn't miss that delivery. With a pull of the tab, his two-second chug was on, and he capped it with a defiant raising of his beer-holding left hand. Indeed, it tasted great at the conclusion of another productive race. 'And two podiums,' Ferrucci said of his recent run of success in the NTT INDYCAR SERIES. 'We're back to where we were at the end of last year. I feel it. 'I've got to get my qualifying performances up, but until then I like padding my points for passing.' Ferrucci finished fifth in the Indianapolis 500 presented by Gainbridge, second in the Chevrolet Detroit Grand Prix presented by Lear and fifth in the Bommarito Automotive Group 500 presented by Axalta and Valvoline at World Wide Technology Raceway. He is tied with Colton Herta of Andretti Global w/Curb-Agajanian for ninth in the standings, and they are only six points behind Team Penske's Scott McLaughlin for eighth. To secure this podium finish, Ferrucci had to climb from the 18th starting position and then overcome not only a stall on a pit stop but had to stretch his last supply of fuel 16 laps. Conventional wisdom was that the maximum any driver could manage was 15 laps, and that's how far race winner Alex Palou of Chip Ganassi Racing did. So, Ferrucci went a lap farther, and he didn't have the benefit of drafting off a teammate as Palou did with Scott Dixon. Ferrucci admitted it was stressful not knowing if his fuel tank would grant what he asked of it, and he radioed to his crew to lay off any conversation, including a lap countdown. 'I told him, 'Listen, I've got to focus because this is getting stressful,'' the driver said of his strategist. 'He let me drive.' Ferrucci dedicated the podium finish to Marlyne Sexton, the team's longtime friend and supporter who passed away June 11 at age 86. Her memory was celebrated on the sidepod of the team's car. Team president Larry Foyt called honoring Sexton with this performance 'unbelievably special – it's hard not to get emotional.' Said Ferrucci: 'She was running with us today. I'm very proud. Yeah, this one tastes a little bit sweeter.' recommended
